Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 11Phase NA 3Phase 4 3Phase 1/2 3Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Endocrine 1

Conditions

Breast Neoplasms 18Carcinoma, Renal Cell 8Neuroendocrine Tumors 6Tuberous Sclerosis 3Neoplasm Metastasis 3Kidney Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Seizures 2Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma 2Carcinoid Tumor 2Astrocytoma 2von Hippel-Lindau Disease 1Unilateral Breast Neoplasms 1Tuberous Sclerosis Complex-associated Refractory Seizures 1Tuberous Sclerosis 2 1Thymus Neoplasms 1Stomach Diseases 1Skin Neoplasms 1Renal Cell Cancer Metastatic 1Recurrence 1Prostatic Neoplasms 1Primary Non-metastatic Breast Cancer 1Polycystic Kidney, Autosomal Dominant 1Malignant Carcinoid Syndrome 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Everolimus × Clear all
NCT03839940 2025-01-29

MIST

Alliance for Clinical Trials in Oncology

Phase 3 Terminated
39 enrolled 18 charts
Tumor-Agnostic

Neoplasms

NCT00412061 2014-11-21

RADIANT-2

Novartis

Phase 3 Completed
429 enrolled 13 charts
Endocrine

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡